Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Polynovo ( (AU:PNV) ) has provided an update.
PolyNovo announced a special briefing featuring Professor Toby Coates, who successfully used PolyNovo’s NovoSorb BTM in a groundbreaking islet cell transplant for a Type 1 diabetic patient. This development highlights NovoSorb’s versatility and potential to enter new markets, reinforcing PolyNovo’s innovative position in the medical technology industry.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo is a disruptive medical technology company based in Melbourne, Australia, specializing in products that simplify the management of acute complex wounds. The company focuses on redefining healing with significantly improved patient outcomes across various wound types and has treated over 70,000 patients in 46 countries. PolyNovo is committed to growth through new products, indications, and market expansions.
Average Trading Volume: 2,090,089
Technical Sentiment Signal: Sell
Current Market Cap: A$787.6M
For detailed information about PNV stock, go to TipRanks’ Stock Analysis page.